Genprex
Genprex, Inc. is a clinical-stage gene therapy company dedicated to developing innovative therapies for cancer and diabetes. They focus on leveraging proprietary technology platforms, including non-viral vectors, to create life-changing treatments. The company is actively involved in clinical trials, research collaborations, and advancing gene therapy technologies, with a strong commitment to reprogramming the course of lung cancer and other cancers, as well as addressing diabetes.
Industries
Nr. of Employees
small (1-50)
Products
Systemic plasmid DNA therapy using nonviral nanoparticle delivery (tumor suppressor replacement)
A systemically administered plasmid DNA therapeutic formulated in nonviral nanoparticles intended to restore tumor suppressor activity for oncology indications and to be evaluated in combination with targeted and immune therapies.
Gene-based therapy candidate for glucose regulation
A gene therapy approach developed to stabilize or improve glucose control in type 1 and type 2 diabetes, supported by preclinical data and academic licensing.
Early-stage investigational gene therapy programs
Preclinical and early clinical gene therapy candidates targeting oncology and other indications to expand the development pipeline and diversify indications.
Systemic plasmid DNA therapy using nonviral nanoparticle delivery (tumor suppressor replacement)
A systemically administered plasmid DNA therapeutic formulated in nonviral nanoparticles intended to restore tumor suppressor activity for oncology indications and to be evaluated in combination with targeted and immune therapies.
Gene-based therapy candidate for glucose regulation
A gene therapy approach developed to stabilize or improve glucose control in type 1 and type 2 diabetes, supported by preclinical data and academic licensing.
Early-stage investigational gene therapy programs
Preclinical and early clinical gene therapy candidates targeting oncology and other indications to expand the development pipeline and diversify indications.
Services
Sponsored research collaborations
Structured sponsored research agreements with academic centers to support preclinical and translational studies for gene therapy programs.
Technology licensing and partnership agreements
In-licensing and option agreements to acquire additional gene therapy technologies and enter partnerships to expand program scope and indications.
Sponsored research collaborations
Structured sponsored research agreements with academic centers to support preclinical and translational studies for gene therapy programs.
Technology licensing and partnership agreements
In-licensing and option agreements to acquire additional gene therapy technologies and enter partnerships to expand program scope and indications.
Expertise Areas
- Gene therapy development
- Nonviral nucleic acid delivery
- Oncology therapeutics (NSCLC, glioblastoma, small cell lung cancer)
- Gene-based metabolic therapeutics (diabetes)
Key Technologies
- Nonviral nanoparticle delivery
- Plasmid DNA therapeutics
- Tumor suppressor gene replacement
- Immunogene therapy approaches